Literature DB >> 24890523

Targeted therapies in cancer and mechanisms of resistance.

Simona Corso1, Silvia Giordano.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24890523     DOI： 10.1007/s00109-014-1171-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  15 in total

Review 1.  Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.

Authors:  Arjan Gower; Yisong Wang; Giuseppe Giaccone
Journal:  J Mol Med (Berl)       Date:  2014-05-23       Impact factor: 4.599

Review 2.  Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.

Authors:  I Bernard Weinstein; Andrew K Joe
Journal:  Nat Clin Pract Oncol       Date:  2006-08

Review 3.  Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy.

Authors:  Francesca Carlomagno; Mario Chiariello
Journal:  J Mol Med (Berl)       Date:  2014-06-08       Impact factor: 4.599

Review 4.  Timeline: Chemotherapy and the war on cancer.

Authors:  Bruce A Chabner; Thomas G Roberts
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

5.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

7.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

Review 8.  Cancer drug resistance: an evolving paradigm.

Authors:  Caitriona Holohan; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

9.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

Review 10.  Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.

Authors:  Simonetta M Leto; Livio Trusolino
Journal:  J Mol Med (Berl)       Date:  2014-05-10       Impact factor: 4.599
View more
  3 in total

1.  Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.

Authors:  Friedemann Schad; Jan Axtner; Matthias Kröz; Harald Matthes; Megan L Steele
Journal:  Integr Cancer Ther       Date:  2016-12-01       Impact factor: 3.279

Review 2.  Colorectal Cancer: From Genetic Landscape to Targeted Therapy.

Authors:  Mouade El Bali; Joaira Bakkach; Mohcine Bennani Mechita
Journal:  J Oncol       Date:  2021-07-06       Impact factor: 4.375

3.  The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.

Authors:  Xuejing Shao; Yujia Liu; Yangling Li; Miao Xian; Qian Zhou; Bo Yang; Meidan Ying; Qiaojun He
Journal:  Sci Rep       Date:  2016-04-14       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.